Fairvalue-Calculator Fairvalue-Calculator
EN DE

VivoSim Labs, Inc (VIVS) Fair Value & Analysis

Healthcare · US · Market cap $3.2M

Price$1.09
Fair Value$0.9834
Upside-9.8%
Quality95/100
Evidence: Low Range $0.7374 – $1.23

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

VivoSim Labs, Inc (VIVS) currently trades at $1.09, while our model-based Fair Value estimate is $0.9834 — implying the stock looks roughly 9.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human norma…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is VivoSim Labs, Inc (VIVS) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.9834 versus a price of $1.09 — about −10% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VIVS?
Our 21-model fair value for VivoSim Labs, Inc is $0.9834 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.09.
What is the quality score of VIVS?
VivoSim Labs, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.